To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial.
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial / Van der Heijde, D; Schiff, M. H; Sieper, J; Kivitz, A. J; Wong, R. L; Kupper, H; Dijkmans, B. A. C; Mease, P. J; Davis, J. C; Atlas, ; Salvarani, Carlo. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 68:6(2009), pp. 922-929. [10.1136/ard.2007.087270]
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
SALVARANI, CARLO
2009
Abstract
To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial.
| File | Dimensione | Formato | |
|---|---|---|---|
|
922.full.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
214.45 kB
Formato
Adobe PDF
|
214.45 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
